Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...

The pharma sector in Q3 2025 presents opportunities in oncology, highlighted by its prominence in M&A deals despite a drop in overall deal volume. The surge in deal value indicates robust interest and ...